ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Enzon Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was $0.006. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.18 for the trailing ten years ended in Dec. 2023.
During the past 12 months, Enzon Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was -14.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Enzon Pharmaceuticals was 61.60% per year. The lowest was -14.90% per year. And the median was 2.20% per year.
As of today (2024-04-29), Enzon Pharmaceuticals's current stock price is $0.08345. Enzon Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.18. Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 0.46.
During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Enzon Pharmaceuticals was 9.32. The lowest was 0.30. And the median was 1.24.
The historical data trend for Enzon Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | 0.21 | 0.21 | 0.21 | 0.20 | 0.18 |
For the Biotechnology subindustry, Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Enzon Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.006 | / | 129.4194 | * | 129.4194 | |
= | 0.006 |
Current CPI (Dec. 2023) = 129.4194.
Enzon Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | 0.185 | 99.695 | 0.240 |
201406 | 0.150 | 100.560 | 0.193 |
201409 | 0.170 | 100.428 | 0.219 |
201412 | 0.226 | 99.070 | 0.295 |
201503 | 0.105 | 99.621 | 0.136 |
201506 | 0.095 | 100.684 | 0.122 |
201509 | 0.076 | 100.392 | 0.098 |
201512 | 0.056 | 99.792 | 0.073 |
201603 | -0.044 | 100.470 | -0.057 |
201606 | 0.034 | 101.688 | 0.043 |
201609 | 0.038 | 101.861 | 0.048 |
201612 | 0.031 | 101.863 | 0.039 |
201703 | 0.010 | 102.862 | 0.013 |
201706 | 0.071 | 103.349 | 0.089 |
201709 | -0.006 | 104.136 | -0.007 |
201712 | 0.071 | 104.011 | 0.088 |
201803 | -0.005 | 105.290 | -0.006 |
201806 | -0.006 | 106.317 | -0.007 |
201809 | -0.005 | 106.507 | -0.006 |
201812 | -0.005 | 105.998 | -0.006 |
201903 | -0.007 | 107.251 | -0.008 |
201906 | -0.004 | 108.070 | -0.005 |
201909 | 0.150 | 108.329 | 0.179 |
201912 | 0.017 | 108.420 | 0.020 |
202003 | -0.007 | 108.902 | -0.008 |
202006 | 0.017 | 108.767 | 0.020 |
202009 | -0.007 | 109.815 | -0.008 |
202012 | -0.008 | 109.897 | -0.009 |
202103 | 0.001 | 111.754 | 0.001 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | -0.004 | 115.734 | -0.004 |
202112 | -0.003 | 117.630 | -0.003 |
202203 | -0.003 | 121.301 | -0.003 |
202206 | -0.009 | 125.017 | -0.009 |
202209 | 0.001 | 125.227 | 0.001 |
202212 | 0.002 | 125.222 | 0.002 |
202303 | 0.002 | 127.348 | 0.002 |
202306 | 0.003 | 128.729 | 0.003 |
202309 | 0.006 | 129.860 | 0.006 |
202312 | 0.006 | 129.419 | 0.006 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 0.08345 | / | 0.18 | |
= | 0.46 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Enzon Pharmaceuticals was 9.32. The lowest was 0.30. And the median was 1.24.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By Marketwired Marketwired • 09-03-2020
By gurufocus 10qk • 08-09-2010
By guruek guruek • 11-15-2009
By gurufocus 10qk • 03-16-2011
By gurufocus Todd Sullivan • 03-14-2008
By Holly LaFon Holly LaFon • 01-10-2014
By Marketwired Marketwired • 01-04-2021
By GuruFocus Research GuruFocus Editor • 06-22-2010
By Marketwired Marketwired • 08-22-2020
By Marketwired Marketwired • 09-16-2020